Phio Pharmaceuticals (PHIO) Common Equity (2011 - 2026)
Phio Pharmaceuticals' (PHIO) quarterly Common Equity came in at $16.5 million in Q1 2026, up 35.27% YoY from $12.2 million in Q1 2025, and down 18.29% on a QoQ basis from $20.1 million in Q4 2025.
Phio Pharmaceuticals (PHIO) Common Equity (2011 - 2026) Analysis & Trends
Phio Pharmaceuticals (PHIO) has 16 years of Common Equity data on file, last reported at $16.5 million in Q1 2026.
- Quarterly Common Equity rose 35.27% year-over-year to $16.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $16.5 million (up 35.27% YoY) and the FY2025 annual result came in at $20.1 million, up 326.57% from the prior year.
- Common Equity eased to $16.5 million in Q1 2026, from $20.1 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $20.1 million in Q4 2025 to a low of $3.8 million in Q2 2024.
- A 5-year average of $10.6 million and a median of $9.9 million in 2023 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2023 — Common Equity plunged 62.41% — and 2025, when it surged 326.57%.
- Tracing PHIO's Common Equity over 5 years: stood at $10.8 million in 2022, then dropped by 28.68% to $7.7 million in 2023, then tumbled by 38.9% to $4.7 million in 2024, then surged by 326.57% to $20.1 million in 2025, then slipped by 18.29% to $16.5 million in 2026.
- The last three Common Equity figures came in at $16.5 million (Q1 2026), $20.1 million (Q4 2025), and $9.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.35 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 757.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.79 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 22.38 Bn |
| 10 | Phio Pharmaceuticals | 14.06 Mn | 14.06 Mn | - | 12.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12.60 Mn |
| Mar 31, 2026 | 16.46 Mn |
| Dec 31, 2025 | 20.15 Mn |
| Sep 30, 2025 | 9.84 Mn |
| Jun 30, 2025 | 10.10 Mn |
| Mar 31, 2025 | 12.17 Mn |
| Dec 31, 2024 | 4.72 Mn |
| Sep 30, 2024 | 4.95 Mn |
| Jun 30, 2024 | 3.77 Mn |
| Mar 31, 2024 | 5.60 Mn |
| Dec 31, 2023 | 7.73 Mn |
| Sep 30, 2023 | 7.21 Mn |
| Jun 30, 2023 | 9.90 Mn |
| Mar 31, 2023 | 7.31 Mn |
| Dec 31, 2022 | 10.84 Mn |
| Sep 30, 2022 | 13.53 Mn |
| Jun 30, 2022 | 17.00 Mn |
| Mar 31, 2022 | 19.45 Mn |
| Dec 31, 2021 | 21.93 Mn |
| Sep 30, 2021 | 25.25 Mn |